BR112020006931A2 - derivados de àcido glucônico para uso no tratamento e/ou prevenção de infecções microbianas - Google Patents
derivados de àcido glucônico para uso no tratamento e/ou prevenção de infecções microbianas Download PDFInfo
- Publication number
- BR112020006931A2 BR112020006931A2 BR112020006931-0A BR112020006931A BR112020006931A2 BR 112020006931 A2 BR112020006931 A2 BR 112020006931A2 BR 112020006931 A BR112020006931 A BR 112020006931A BR 112020006931 A2 BR112020006931 A2 BR 112020006931A2
- Authority
- BR
- Brazil
- Prior art keywords
- fact
- compound according
- infection
- compound
- vaginal
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 142
- 230000000813 microbial effect Effects 0.000 title claims abstract description 54
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 229
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 230000032770 biofilm formation Effects 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 78
- 241000222122 Candida albicans Species 0.000 claims description 51
- 206010017533 Fungal infection Diseases 0.000 claims description 40
- 208000031888 Mycoses Diseases 0.000 claims description 39
- 239000004310 lactic acid Substances 0.000 claims description 34
- 235000014655 lactic acid Nutrition 0.000 claims description 34
- 208000035143 Bacterial infection Diseases 0.000 claims description 31
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 31
- 125000001931 aliphatic group Chemical group 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 208000002474 Tinea Diseases 0.000 claims description 21
- 239000007943 implant Substances 0.000 claims description 21
- 201000004624 Dermatitis Diseases 0.000 claims description 19
- 206010007134 Candida infections Diseases 0.000 claims description 18
- 201000003984 candidiasis Diseases 0.000 claims description 18
- 208000003322 Coinfection Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 15
- 229940121375 antifungal agent Drugs 0.000 claims description 14
- 239000004599 antimicrobial Substances 0.000 claims description 14
- 230000002538 fungal effect Effects 0.000 claims description 14
- 150000002596 lactones Chemical class 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- -1 nail polish Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 10
- 241000194017 Streptococcus Species 0.000 claims description 9
- 241000893966 Trichophyton verrucosum Species 0.000 claims description 9
- 208000032343 candida glabrata infection Diseases 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241000223238 Trichophyton Species 0.000 claims description 8
- 210000002683 foot Anatomy 0.000 claims description 8
- 210000000282 nail Anatomy 0.000 claims description 8
- 206010012504 Dermatophytosis Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 241001460074 Microsporum distortum Species 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 239000003429 antifungal agent Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 208000007287 cheilitis Diseases 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000002453 shampoo Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010046914 Vaginal infection Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 239000002324 mouth wash Substances 0.000 claims description 5
- 229940051866 mouthwash Drugs 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 241000207202 Gardnerella Species 0.000 claims description 4
- 208000007514 Herpes zoster Diseases 0.000 claims description 4
- 206010021639 Incontinence Diseases 0.000 claims description 4
- 206010056131 Tinea versicolour Diseases 0.000 claims description 4
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 239000004053 dental implant Substances 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 229940044959 vaginal cream Drugs 0.000 claims description 4
- 239000000522 vaginal cream Substances 0.000 claims description 4
- 229940044952 vaginal foam Drugs 0.000 claims description 4
- 239000000259 vaginal foam Substances 0.000 claims description 4
- 229940044950 vaginal gel Drugs 0.000 claims description 4
- 239000000029 vaginal gel Substances 0.000 claims description 4
- 229940098946 vaginal ointment Drugs 0.000 claims description 4
- 229940044953 vaginal ring Drugs 0.000 claims description 4
- 239000006213 vaginal ring Substances 0.000 claims description 4
- 229940120293 vaginal suppository Drugs 0.000 claims description 4
- 239000006216 vaginal suppository Substances 0.000 claims description 4
- 230000002861 ventricular Effects 0.000 claims description 4
- 201000002909 Aspergillosis Diseases 0.000 claims description 3
- 208000036641 Aspergillus infections Diseases 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 208000010195 Onychomycosis Diseases 0.000 claims description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 3
- 208000005107 Premature Birth Diseases 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241000130764 Tinea Species 0.000 claims description 3
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 3
- 201000008100 Vaginitis Diseases 0.000 claims description 3
- 206010008323 cervicitis Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 206010040882 skin lesion Diseases 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 201000005882 tinea unguium Diseases 0.000 claims description 3
- 229940044977 vaginal tablet Drugs 0.000 claims description 3
- 239000000003 vaginal tablet Substances 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 2
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 206010002515 Animal bite Diseases 0.000 claims description 2
- 206010003399 Arthropod bite Diseases 0.000 claims description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 2
- 241000606125 Bacteroides Species 0.000 claims description 2
- 206010005098 Blastomycosis Diseases 0.000 claims description 2
- 206010005913 Body tinea Diseases 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 206010008803 Chromoblastomycosis Diseases 0.000 claims description 2
- 208000015116 Chromomycosis Diseases 0.000 claims description 2
- 241000223205 Coccidioides immitis Species 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 201000000297 Erysipelas Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 206010016936 Folliculitis Diseases 0.000 claims description 2
- 206010017553 Furuncle Diseases 0.000 claims description 2
- 201000002563 Histoplasmosis Diseases 0.000 claims description 2
- 206010021531 Impetigo Diseases 0.000 claims description 2
- 206010022013 Ingrowing nail Diseases 0.000 claims description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 2
- 206010027205 Meningitis candida Diseases 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 241001480037 Microsporum Species 0.000 claims description 2
- 241000203736 Mobiluncus Species 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 241000588653 Neisseria Species 0.000 claims description 2
- 208000007027 Oral Candidiasis Diseases 0.000 claims description 2
- 206010033767 Paracoccidioides infections Diseases 0.000 claims description 2
- 201000000301 Paracoccidioidomycosis Diseases 0.000 claims description 2
- 206010034016 Paronychia Diseases 0.000 claims description 2
- 241000029132 Paronychia Species 0.000 claims description 2
- 241000191992 Peptostreptococcus Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 206010041736 Sporotrichosis Diseases 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 208000004374 Tick Bites Diseases 0.000 claims description 2
- 208000007712 Tinea Versicolor Diseases 0.000 claims description 2
- 206010043866 Tinea capitis Diseases 0.000 claims description 2
- 201000010618 Tinea cruris Diseases 0.000 claims description 2
- 206010049591 Tinea imbricata Diseases 0.000 claims description 2
- 206010067197 Tinea manuum Diseases 0.000 claims description 2
- 241000589884 Treponema pallidum Species 0.000 claims description 2
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 2
- 241000224527 Trichomonas vaginalis Species 0.000 claims description 2
- 206010044620 Trichomoniasis Diseases 0.000 claims description 2
- 241000202898 Ureaplasma Species 0.000 claims description 2
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 201000003465 angular cheilitis Diseases 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 229960005074 butoconazole Drugs 0.000 claims description 2
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 201000003486 coccidioidomycosis Diseases 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960001274 fenticonazole Drugs 0.000 claims description 2
- 229960004884 fluconazole Drugs 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 208000024386 fungal infectious disease Diseases 0.000 claims description 2
- 208000003512 furunculosis Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 210000004013 groin Anatomy 0.000 claims description 2
- 210000003709 heart valve Anatomy 0.000 claims description 2
- 229960004849 isoconazole Drugs 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 230000001617 migratory effect Effects 0.000 claims description 2
- 210000002445 nipple Anatomy 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- 229960000988 nystatin Drugs 0.000 claims description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 201000000508 pityriasis versicolor Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 210000004761 scalp Anatomy 0.000 claims description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
- 208000006379 syphilis Diseases 0.000 claims description 2
- 229960000580 terconazole Drugs 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 201000003875 tinea corporis Diseases 0.000 claims description 2
- 201000004647 tinea pedis Diseases 0.000 claims description 2
- 229960004214 tioconazole Drugs 0.000 claims description 2
- 210000004906 toe nail Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 230000001755 vocal effect Effects 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims 2
- 239000002250 absorbent Substances 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 241001633064 Atopobium vaginae Species 0.000 claims 1
- 206010014669 Endocarditis candida Diseases 0.000 claims 1
- 241000555676 Malassezia Species 0.000 claims 1
- 208000009675 Perioral Dermatitis Diseases 0.000 claims 1
- 241000223229 Trichophyton rubrum Species 0.000 claims 1
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 1
- 239000007933 dermal patch Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000009642 tinea barbae Diseases 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 109
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 68
- 235000012208 gluconic acid Nutrition 0.000 description 68
- 239000000174 gluconic acid Substances 0.000 description 61
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 52
- 229950006191 gluconic acid Drugs 0.000 description 45
- 239000002609 medium Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 32
- 229960000448 lactic acid Drugs 0.000 description 30
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 24
- 241000222126 [Candida] glabrata Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 229960004106 citric acid Drugs 0.000 description 16
- 235000015165 citric acid Nutrition 0.000 description 16
- 229940095731 candida albicans Drugs 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000007853 buffer solution Substances 0.000 description 13
- 238000011161 development Methods 0.000 description 10
- 241000233866 Fungi Species 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 239000002028 Biomass Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 241000218492 Lactobacillus crispatus Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 241000207201 Gardnerella vaginalis Species 0.000 description 7
- 241001324870 Lactobacillus iners Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 241000235645 Pichia kudriavzevii Species 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- QXKAIJAYHKCRRA-UHFFFAOYSA-N D-lyxonic acid Natural products OCC(O)C(O)C(O)C(O)=O QXKAIJAYHKCRRA-UHFFFAOYSA-N 0.000 description 5
- QXKAIJAYHKCRRA-FLRLBIABSA-N D-xylonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-FLRLBIABSA-N 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000222178 Candida tropicalis Species 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 3
- 241001646716 Escherichia coli K-12 Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930182821 L-proline Natural products 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002303 citric acid monohydrate Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000011007 phosphoric acid Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 2
- 206010060937 Amniotic cavity infection Diseases 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000675278 Candida albicans SC5314 Species 0.000 description 2
- 208000008158 Chorioamnionitis Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010036595 Premature delivery Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 125000000422 delta-lactone group Chemical group 0.000 description 2
- 125000000457 gamma-lactone group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000007222 ypd medium Substances 0.000 description 2
- CFBVWCHTNQHZLT-UHFFFAOYSA-N 4-methoxy-5-[3-(2-methoxy-4-nitro-5-sulfophenyl)-5-(phenylcarbamoyl)tetrazol-3-ium-2-yl]-2-nitrobenzenesulfonate Chemical class COC1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C=C1N1[N+](C=2C(=CC(=C(C=2)S(O)(=O)=O)[N+]([O-])=O)OC)=NC(C(=O)NC=2C=CC=CC=2)=N1 CFBVWCHTNQHZLT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 244000034356 Aframomum angustifolium Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000193818 Atopobium Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 108700025774 Candida albicans ECE1 Proteins 0.000 description 1
- 241000798862 Candida glabrata CBS 138 Species 0.000 description 1
- 206010053166 Candida sepsis Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036195 Porphyromonas infections Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241001265626 Streptococcus agalactiae CCUG 29376 Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940037645 staphylococcus epidermidis Drugs 0.000 description 1
- 229940030998 streptococcus agalactiae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009105 vegetative growth Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polyesters Or Polycarbonates (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195192 | 2017-10-06 | ||
| EP17195192.4 | 2017-10-06 | ||
| PCT/EP2018/077129 WO2019068862A1 (en) | 2017-10-06 | 2018-10-05 | GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND / OR PREVENTION OF MICROBIAL INFECTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020006931A2 true BR112020006931A2 (pt) | 2020-10-06 |
Family
ID=60185986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020006931-0A BR112020006931A2 (pt) | 2017-10-06 | 2018-10-05 | derivados de àcido glucônico para uso no tratamento e/ou prevenção de infecções microbianas |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11612584B2 (enExample) |
| EP (1) | EP3691625B1 (enExample) |
| JP (1) | JP7424636B2 (enExample) |
| KR (1) | KR102650182B1 (enExample) |
| CN (1) | CN111182895B (enExample) |
| AU (1) | AU2018346361B2 (enExample) |
| BR (1) | BR112020006931A2 (enExample) |
| CA (1) | CA3078451A1 (enExample) |
| CL (1) | CL2020000859A1 (enExample) |
| EA (1) | EA202090750A1 (enExample) |
| ES (1) | ES3017694T3 (enExample) |
| HU (1) | HUE070746T2 (enExample) |
| IL (1) | IL273297B2 (enExample) |
| MX (1) | MX2020003660A (enExample) |
| MY (1) | MY205944A (enExample) |
| PH (1) | PH12020550222A1 (enExample) |
| PL (1) | PL3691625T3 (enExample) |
| SG (1) | SG11202002494WA (enExample) |
| UA (1) | UA126590C2 (enExample) |
| WO (1) | WO2019068862A1 (enExample) |
| ZA (1) | ZA202001605B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3017694T3 (en) | 2017-10-06 | 2025-05-13 | Gedea Biotech Ab | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections |
| MY208388A (en) | 2019-04-05 | 2025-05-06 | Gedea Biotech Ab | Vaginal tablet formulation |
| CN114751878B (zh) * | 2022-03-29 | 2023-06-16 | 青岛农业大学 | 一种BcTol1基因靶向剂及其应用 |
| WO2024261110A1 (en) * | 2023-06-22 | 2024-12-26 | Gedea Biotech Ab | Compositions for promoting growth of lactobacillus crispatus |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1278868B1 (it) | 1995-10-27 | 1997-11-28 | Sanitaria Scaligera Spa | Metodo per l'ottenimento di un materiale riassorbibile atto ad essere utilizzato come elemento di rivestimento per la prevenzione di |
| AUPP839499A0 (en) | 1999-01-29 | 1999-02-25 | Australian National University, The | A method for controlling plant pathogens, and agents useful for same |
| JP3745612B2 (ja) | 2000-10-31 | 2006-02-15 | 西川ゴム工業株式会社 | ポリヒドロキシカルボン酸の製造方法 |
| US20030017207A1 (en) | 2001-05-01 | 2003-01-23 | Lin Shun Y. | Compositions and methods for treating vulvovaginitis and vaginosis |
| US20060172007A1 (en) * | 2001-05-01 | 2006-08-03 | Nawaz Ahmad | Compositions and methods for reducing vaginal pH |
| US20060105008A1 (en) | 2002-03-28 | 2006-05-18 | Nawaz Ahmad | Compositions and methods for reducing vaginal pH |
| CA2487270C (en) | 2002-06-21 | 2010-10-26 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
| US7569530B1 (en) | 2003-06-20 | 2009-08-04 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
| US7547454B2 (en) * | 2002-11-07 | 2009-06-16 | Shyam K Gupta | Hydroxy acid complexes for antiaging and skin renovation |
| US20040126369A1 (en) * | 2002-12-30 | 2004-07-01 | Richard Payne | Delivery of peroxide-generating enzymes to the vaginal tract |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US20050260243A1 (en) * | 2004-04-26 | 2005-11-24 | The Procter & Gamble Company | Method of treating microbial plant diseases |
| US20050271711A1 (en) | 2004-04-26 | 2005-12-08 | The Procter & Gamble Company | Therapeutic antimicrobial compositions and methods |
| AU2006209263A1 (en) | 2005-09-12 | 2007-03-29 | Mcneil-Ppc, Inc. | Anhydrous composition containing an acid-acid buffer system |
| US20070059278A1 (en) | 2005-09-12 | 2007-03-15 | Nawaz Ahmad | Anhydrous composition containing an acid-acid buffer system |
| US20080058421A1 (en) * | 2006-09-05 | 2008-03-06 | John Alex Lopes | Compositions for cleaning and disinfecting nasal tract and sinus cavity |
| WO2008108834A2 (en) * | 2006-11-09 | 2008-09-12 | Northwestern University | Inhibitors of the mevalonate pathway of streptococcus pneumoniae |
| JP2008283893A (ja) * | 2007-05-16 | 2008-11-27 | Sumitomo Chemical Co Ltd | 家禽用コクシジウム感染抑制剤及びそれを用いたコクシジウム感染抑制方法 |
| US20100285095A1 (en) * | 2009-05-05 | 2010-11-11 | Kimberly Ann Nemeth | Hygiene Article Having Calcium Sugar Acid Salt |
| CN102070774B (zh) | 2010-11-25 | 2012-08-22 | 华南师范大学 | 单糖或其糖醇与乳酸的共聚物的制备方法 |
| MX2013012745A (es) | 2011-05-02 | 2014-12-05 | Aptalis Pharmatech Inc | Composiciones en forma de comprmido de disolución rápida para administración vaginal. |
| MY172685A (en) | 2013-11-08 | 2019-12-10 | Suzhou Osel Bio Pharm Co Ltd | A lactobacillus crispatus and application thereof |
| DK178786B1 (en) * | 2015-03-11 | 2017-02-06 | Dantrace-Danfeed Ivs | Use of zinc and copper gluconate in the treatment of methicillin-resistant staphylococcus aureus |
| DK3439633T3 (da) * | 2016-04-06 | 2021-12-20 | Gedea Biotech Ab | Glucono delta-lacton til behandling af vaginale svampeinfektioner |
| JP7219712B2 (ja) | 2016-10-13 | 2023-02-08 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | 膣送達のための凍結乾燥医薬組成物 |
| KR101841976B1 (ko) | 2017-06-07 | 2018-05-14 | 조영진 | 식물 추출물을 포함하는 항진균 및 항균 조성물 |
| ES3017694T3 (en) | 2017-10-06 | 2025-05-13 | Gedea Biotech Ab | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections |
| MY208388A (en) | 2019-04-05 | 2025-05-06 | Gedea Biotech Ab | Vaginal tablet formulation |
-
2018
- 2018-10-05 ES ES18788687T patent/ES3017694T3/es active Active
- 2018-10-05 EA EA202090750A patent/EA202090750A1/ru unknown
- 2018-10-05 KR KR1020207010202A patent/KR102650182B1/ko active Active
- 2018-10-05 AU AU2018346361A patent/AU2018346361B2/en active Active
- 2018-10-05 MX MX2020003660A patent/MX2020003660A/es unknown
- 2018-10-05 WO PCT/EP2018/077129 patent/WO2019068862A1/en not_active Ceased
- 2018-10-05 MY MYPI2020001657A patent/MY205944A/en unknown
- 2018-10-05 US US16/753,899 patent/US11612584B2/en active Active
- 2018-10-05 UA UAA202002422A patent/UA126590C2/uk unknown
- 2018-10-05 CA CA3078451A patent/CA3078451A1/en active Pending
- 2018-10-05 PL PL18788687.4T patent/PL3691625T3/pl unknown
- 2018-10-05 SG SG11202002494WA patent/SG11202002494WA/en unknown
- 2018-10-05 JP JP2020519028A patent/JP7424636B2/ja active Active
- 2018-10-05 EP EP18788687.4A patent/EP3691625B1/en active Active
- 2018-10-05 BR BR112020006931-0A patent/BR112020006931A2/pt unknown
- 2018-10-05 HU HUE18788687A patent/HUE070746T2/hu unknown
- 2018-10-05 CN CN201880065162.XA patent/CN111182895B/zh active Active
- 2018-10-05 IL IL273297A patent/IL273297B2/en unknown
-
2020
- 2020-03-13 ZA ZA2020/01605A patent/ZA202001605B/en unknown
- 2020-03-31 CL CL2020000859A patent/CL2020000859A1/es unknown
- 2020-04-06 PH PH12020550222A patent/PH12020550222A1/en unknown
-
2023
- 2023-02-02 US US18/163,321 patent/US12226396B2/en active Active
-
2025
- 2025-01-08 US US19/013,187 patent/US20250144070A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102650182B1 (ko) | 2024-03-21 |
| US20200253925A1 (en) | 2020-08-13 |
| SG11202002494WA (en) | 2020-04-29 |
| PH12020550222A1 (en) | 2021-02-15 |
| MX2020003660A (es) | 2020-08-03 |
| UA126590C2 (uk) | 2022-11-02 |
| CA3078451A1 (en) | 2019-04-11 |
| PL3691625T3 (pl) | 2025-05-12 |
| JP2020536862A (ja) | 2020-12-17 |
| ES3017694T3 (en) | 2025-05-13 |
| EP3691625A1 (en) | 2020-08-12 |
| CN111182895A (zh) | 2020-05-19 |
| IL273297B1 (en) | 2024-02-01 |
| CL2020000859A1 (es) | 2020-10-02 |
| AU2018346361B2 (en) | 2024-07-25 |
| US11612584B2 (en) | 2023-03-28 |
| ZA202001605B (en) | 2023-12-20 |
| AU2018346361A1 (en) | 2020-05-14 |
| JP7424636B2 (ja) | 2024-01-30 |
| US12226396B2 (en) | 2025-02-18 |
| US20230181523A1 (en) | 2023-06-15 |
| EP3691625B1 (en) | 2025-02-19 |
| HUE070746T2 (hu) | 2025-07-28 |
| MY205944A (en) | 2024-11-21 |
| US20250144070A1 (en) | 2025-05-08 |
| EP3691625C0 (en) | 2025-02-19 |
| WO2019068862A1 (en) | 2019-04-11 |
| EA202090750A1 (ru) | 2020-11-11 |
| CN111182895B (zh) | 2024-05-14 |
| IL273297B2 (en) | 2024-06-01 |
| KR20200060413A (ko) | 2020-05-29 |
| IL273297A (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12226396B2 (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| ES2856831T3 (es) | Una composición que comprende un antibiótico no peptídico y cisteamina | |
| Oliveira et al. | Menthol-based deep eutectic systems as antimicrobial and anti-inflammatory agents for wound healing | |
| TWI446911B (zh) | 含美西特田（ｍａｃｉｔｅｎｔａｎ）之治療組合物 | |
| MX2012004509A (es) | Composicion externa para la piel que comprende una sal y azucar como ingredientes activos para prevenir y tratar la vaginosis y uso de la misma. | |
| ES2896680T3 (es) | Glucono delta lactona para el tratamiento de infecciones fúngicas vaginales | |
| RU2730021C1 (ru) | Средство местного применения для лечения инфекционных вагинитов | |
| AU2019286511B2 (en) | Enhancement of antibacterial actions of a depsipeptide antibiotic using synergistic amounts of boric acid | |
| Li et al. | A targeted pH-responsive micelle based on poly (ethylene glycol) and polycaprolactone for Pseudomonas aeruginosa pneumonia treatment | |
| ES2387440B2 (es) | Formulaciones topicas de anfotericina b y metodo de obtencion | |
| US20220409651A1 (en) | Anti-fungal compositions and methods for using same | |
| HK40029669B (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| JP2019521134A (ja) | 性感染症用組成物 | |
| BR112018070370B1 (pt) | Glucono delta-lactona para tratamento de candidíase vulvovaginal | |
| ITRM20090360A1 (it) | Preparato antimicrobico per uso topico a base di metilgliossale | |
| ITMI20112352A1 (it) | Composizione vaginale a base di proantocianidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |